ALVOTECH
-
USD
(-)
- 15 min delayed data - NASDAQ Stocks
| Open: | - |
| Change: | - |
| Volume: | - |
| Low: | - |
| High: | - |
| High / Low range: | - |
| Type: | Stocks |
| Ticker: | ALVO |
| ISIN: | LU2458332611 |
ALVOTECH news, videos and press releases - Page 6
For more news please use our advanced search feature.
ALVOTECH - More news...
ALVOTECH - More news...
- 05/24/2023 - 09:00 Alvotech and Advanz Pharma extend strategic partnership to commercialize five proposed biosimilars in Europe
- 05/19/2023 - 09:00 Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
- 05/19/2023 - 09:00 Alvotech Reports Financial Results for First three Months of 2023 and Provides Business Update
- 05/17/2023 - 09:00 Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
- 05/17/2023 - 09:00 Alvotech to Participate in Morgan Stanley Annual Sustainable Finance Summit
- 05/15/2023 - 09:00 Alvotech Issues Annual Equality Report Covering 2022
- 05/15/2023 - 09:00 Alvotech Issues Annual Equality Report Covering 2022
- 05/10/2023 - 09:00 Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
- 05/10/2023 - 09:00 Alvotech enters into commercialization agreement with Polifarma for proposed biosimilar to Eylea® (aflibercept)
- 05/05/2023 - 13:00 Alvotech S.A. Annual General Meeting to be held June 6, 2023
- 05/04/2023 - 09:00 Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
- 05/04/2023 - 09:00 Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
- 05/03/2023 - 13:00 Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
- 05/03/2023 - 13:00 Alvotech to Report First Quarter 2023 Financial Results and Recent Business Highlights on May 18, 2023 and Host Conference Call on May 19, 2023 at 8:00 am ET
- 04/26/2023 - 07:45 INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the Firm
- 04/19/2023 - 21:30 Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
- 04/19/2023 - 21:30 Sarah Tanksley Joins Board of Directors for Alvotech hf. and Sandra Casaca Appointed Chief Quality Officer
- 04/14/2023 - 00:45 Alvotech Provides Regulatory Update on AVT02 Biologics License Application
- 04/14/2023 - 00:45 Alvotech Provides Regulatory Update on AVT02 Biologics License Application
- 03/28/2023 - 09:00 Alvotech Provides Update on Corporate Sustainability Framework
- 03/28/2023 - 09:00 Alvotech Provides Update on Corporate Sustainability Framework
- 03/17/2023 - 13:10 Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
- 03/17/2023 - 13:10 Alvotech to Present Clinical Study Data for AVT04, a Proposed Biosimilar to Stelara®, at 2023 American Academy of Dermatology (AAD) Annual Meeting
- 03/01/2023 - 21:30 Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
- 03/01/2023 - 21:30 Alvotech Reports Financial Results for Full Year 2022 and Provides Business Update
- 02/28/2023 - 00:15 Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
- 02/28/2023 - 00:15 Alvotech Announces Webcast of 2022 Full Year Financial Results at 8:00 am ET on March 2, 2023
- 02/14/2023 - 21:01 Updated market making agreement with Landsbankinn for Alvotech shares trading on the Nasdaq Iceland market
- 02/10/2023 - 21:01 Settlement of Alvotech Private Share Placement Completed
- 02/10/2023 - 21:01 Settlement of Alvotech Private Share Placement Completed
